27 results on '"Foucher, Juliette"'
Search Results
2. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
3. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
4. ECAS correlation with metabolic alterations on FDG-PET imaging in ALS
5. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
6. The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review
7. A randomized, double‐blind, placebo‐controlled, phase 2 study to assess safety, tolerability and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
8. Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS)
9. Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan
10. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
11. Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
12. Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
13. Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
14. Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS)
15. A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis
16. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
17. Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements
18. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide
19. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
20. Long‐term prognosis of patients with metabolic (dysfunction)‐associated fatty liver disease by non‐invasive methods
21. Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use
22. SAT-184 - Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
23. WED-469 - Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
24. WED-453 - Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
25. SAT-505 - Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan
26. OS-066 - HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
27. Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.